PRESS RELEASE published on 10/21/2024 at 14:30, 2 years ago XS Financial Expands Into Middle-Market Equipment Finance, Establishing Buy-Side Capital Markets Desk XS Financial announces strategic expansion into mid to large-ticket transactions in middle-market equipment leasing sector. Acquired by Axar and Mavik, enhancing financial strength and flexibility Expansion Capital Markets Equipment Finance XS Financial Middle-Market
PRESS RELEASE published on 10/21/2024 at 14:30, 2 years ago LQR House Inc. Implements Strategic Cost-Cutting Measures Under Activist Investor David Lazar's Leadership LQR House Inc. announces strategic updates including shutting down RareSips NFT platform and ending Bevage LLC partnership under new Director David Lazar to enhance operational efficiency and shareholder value LQR House Inc. Operational Efficiency Shareholder Value Strategic Updates David Lazar
PRESS RELEASE published on 10/21/2024 at 14:30, 2 years ago Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO Catheter Precision announces publication on non-invasive ablation technique STAR for cardiac electrophysiology. VIVO technology shows promising results in targeting heart arrhythmia areas Catheter Precision Cardiac Electrophysiology VIVO Technology STAR Ablation Technique
PRESS RELEASE published on 10/21/2024 at 14:30, 2 years ago Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD Inventiva annonce un abstract "late breaker" sur l'essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine lors du Liver Meeting™ 2024 organisé par l'AASLD Essai Clinique Inventiva Lanifibranor Abstract Empagliflozine
PRESS RELEASE published on 10/21/2024 at 14:30, 2 years ago Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 Inventiva announces late breaker abstract from LEGEND Phase 2 trial evaluating lanifibranor with empagliflozin in MASH at AASLD The Liver Meeting® 2024 Inventiva MASH Lanifibranor LEGEND Phase 2 Empagliflozin
PRESS RELEASE published on 10/21/2024 at 14:25, 2 years ago Director/PDMR Shareholding Britvic plc Directors purchase shares and receive matching shares under Share Incentive Plan. Details of transactions and interests disclosed Transactions Share Incentive Plan Britvic Plc Directors Matching Shares
PRESS RELEASE published on 10/21/2024 at 14:15, 2 years ago Quant Tekel: Defining the Future of Trading Quant Tekel revolutionizes brokerage and prop trading with cutting-edge technology, unmatched experience, and top-tier support for traders, offering opportunities for success and personal growth Cutting-edge Technology Financial Markets Brokerage Prop Trading Quant Tekel
PRESS RELEASE published on 10/21/2024 at 14:01, 2 years ago Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update Mainz Biomed reports 4% revenue increase in Mid-Year 2024 Financial Results with 32% decrease in loss from operations. Company highlights successful studies at ASCO and outlines strategic plan for 2025 Financial Results Corporate Update ColoAlert Mainz Biomed EAArly DETECT
PRESS RELEASE published on 10/21/2024 at 14:00, 2 years ago CANEX Increases Equity Financing CANEX Metals Inc. announces increase in non-brokered private placement to offer up to 3,000,000 Common Shares and 5,250,000 FT Shares for a total of $450,000. Funds to be used for exploration and project advancement Private Placement TSX Venture Exchange Exploration CANEX Metals Inc. Shareholder Demand
PRESS RELEASE published on 10/21/2024 at 13:30, 2 years ago MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
Published on 11/18/2026 at 15:30, 5 hours 24 minutes ago Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
Published on 11/18/2026 at 14:30, 6 hours 24 minutes ago Boron One Announces Non-Binding Heads of Agreement with Multinational Manufacturing Company
Published on 11/18/2026 at 13:35, 7 hours 19 minutes ago ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
Published on 11/18/2026 at 13:30, 7 hours 24 minutes ago NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
Published on 11/18/2026 at 13:20, 7 hours 34 minutes ago Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
Published on 11/18/2026 at 19:30, 1 hour 24 minutes ago LLCP Completes Investment in Empower Technical Services in Partnership with Management
Published on 11/18/2026 at 18:33, 2 hours 21 minutes ago EQS-Adhoc: Medios AG: Medios AG adopts public share buyback program
Published on 11/18/2026 at 18:05, 2 hours 49 minutes ago ALLWYN UNCOVERS 'FEELINGS DEFICIT' AND JOINS FORCES WITH MARIO LOPEZ TO HELP PEOPLE EXPERIENCE MORE FEELINGS THROUGH PLAY
Published on 11/18/2026 at 17:52, 3 hours 2 minutes ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 11/18/2026 at 19:14, 1 hour 40 minutes ago Aéroports de Paris S.A - Favourable binding opinion of the French ART
Published on 11/18/2026 at 19:14, 1 hour 40 minutes ago Aéroports de Paris S.A - Avis conforme favorable de l'ART